# Conformal Medical

> Conformal Medical is a Nashua, New Hampshire medical device company developing the CLAAS AcuFORM System, a next-generation left atrial appendage occlusion (LAAO) implant that uses a proprietary foam matrix to seal the left atrial appendage and reduce stroke risk in patients with non-valvular atrial fibrillation. Its design conforms to a wide range of anatomies with only two device sizes, and is intended to make LAAO a same-day, single-operator procedure that can avoid general anesthesia and transesophageal echocardiography. In February 2026 the company became a wholly owned subsidiary of W. L. Gore & Associates.

- **Founded:** 2016
- **Headquarters:** Nashua, New Hampshire, United States
- **Founders:** Aaron Kaplan (Co-Founder (Chief Medical / Scientific Founder)), Carol Devellian (Co-Founder), Andy Levine (Co-Founder)
- **Team size:** ~56 employees
- **Products:** CLAAS AcuFORM System, CLAAS System (first-generation)
- **Notable:** Named NEVCA's 2023 Powerhouse MedTech Company of the Year, Enrolled 500th patient in the CONFORM pivotal IDE trial (April 2025), Treated 100+ patients with the next-generation AcuFORM System with reported strong deliverability and safety

## Products & services

- **CLAAS AcuFORM System** — A next-generation left atrial appendage occlusion (LAAO) implant built around a proprietary conformable foam matrix. It seals the left atrial appendage to reduce stroke risk in non-valvular AFib patients, conforms to a broad range of anatomies with only two device sizes, and is designed for a same-day, single-operator procedure that can avoid general anesthesia and transesophageal echocardiography (TEE). Investigational / not yet FDA-approved as of early 2026.
- **CLAAS System (first-generation)** — The original conformable foam-based LAA closure platform that established the company's approach to anatomic sealing, with clinical results presented at TCT 2020.

## Achievements

- Named NEVCA's 2023 Powerhouse MedTech Company of the Year
- Enrolled 500th patient in the CONFORM pivotal IDE trial (April 2025)
- Treated 100+ patients with the next-generation AcuFORM System with reported strong deliverability and safety
- Demonstrated ICE-guided LAAO closure in the European GLACE study (no TEE, no general anesthesia)
- Raised approximately $161M in total funding across four rounds
- Acquired by W. L. Gore & Associates in February 2026

## Latest updates

- **2026-02** — W. L. Gore & Associates completed its acquisition of Conformal Medical (February 19, 2026); the company becomes a wholly owned Gore subsidiary.
- **2026-01** — Gore and Conformal Medical announced a definitive acquisition agreement (January 5, 2026).
- **2025-10** — First patient enrolled in the E.U. for the CONFORM pivotal trial with the CLAAS AcuFORM LAAO device.
- **2025-08** — Closed a $32M Series D extension to advance the next-generation AcuFORM technology and pre-commercialization.
- **2025-04** — Enrolled 500th patient in the CONFORM pivotal IDE trial (targeting ~1,600 patients).
- **2024-10** — CLAAS AcuFORM LAAO System featured prominently at TCT 2024.

## Links

- Website: https://conformalmedical.com
- LinkedIn: https://www.linkedin.com/company/conformal-medical
- Twitter/X: https://twitter.com/conformalmed

---

Profile page: https://yespress.io/conformal-medical
Published by YesPress — https://yespress.io
Last updated: 2026-07-21